Clinical Trials Logo

Receptor, ErbB-2 clinical trials

View clinical trials related to Receptor, ErbB-2.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05145179 Not yet recruiting - Receptor, ErbB-2 Clinical Trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

The study will consist of two parts: a dose-escalation part (Part 1) and a dose expansion part (Part 2). In both study parts, SSGJ-705 will be administered,the administration duration may be adjusted based on outcomes of previous patients if necessary) followed by safety, PK, PD, potential anti tumor effects and immunogenicity evaluation.